Crossbow Therapeutics - The cure to cancer. $80m Series A

❓️ What is Crossbow?

Crossbow is aiming to cure cancer via T-cell Mimetics. Their core product, T-Bolt, are molecules that strike tumor cells with unparalleled accuracy and potency. Crossbow is now looking to expand its technology to a much wider range of cancers by targeting all proteins.

🤹 Who are the founders?

1. Geraldine Paulus (Co-Founder & VP of Corp Development and Operations): ex-Senior Associate at MPM BioImpact

2. Todd Foley (Co-Founder): Current Managing Director at MPM BioImpact

3. Patrick Baeuerle (Co-Founder): Current Executive Partner at MPM BioImpact

💰️ More about the funding round:

Crossbow raises its massive $80m Series A in around led by Pfizer Venture Investments and MPM Capital. The fundraising also saw participation from BVF Partners, Mirae Asset Venture Investment, Eli Lilly and Polaris Partners.

💻️ Job openings:

Flow Cytometry operator - Immuno-Oncology (Boston)